Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 19/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.62 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540837 | 0.88 | PARP10 (0.64) | PARP10PARP2PARP4CA1CA2 | |
| SCHEMBL820246 | 0.78 | PARP10 (0.61) | PARP10PARP2PARP4CA1CA2 | |
| SCHEMBL201761 | 0.77 | PARP10 (1.00) | PARP10PARP2PARP4CA1CA2 | |
| Hydrochloric Acid SCHEMBL408766 | 0.75 | PARP10 (0.95) | PARP10PARP2PARP4CA1CA2 | |
| Hydrochloric Acid SCHEMBL4376056 | 0.75 | PARP10 (0.95) | PARP10PARP2PARP4CA1CA2 | |
| SCHEMBL7442028 | 0.72 | PARP10 (0.88) | PARP10PARP2PARP4CA1CA2 | |
| Acetic Acid SCHEMBL28396208 | 0.72 | PARP10 (0.88) | PARP10PARP2PARP4CA1CA2 | |
| SCHEMBL151953 | 0.72 | CA1 (0.67) | CA1CA2ALDH1A1KMT2A | |
| SCHEMBL27571315 | 0.72 | PARP10 (0.88) | PARP10PARP2PARP4CA1CA2 | |
| SCHEMBL5836337 | 0.72 | PARP10 (1.00) | PARP10PARP2PARP4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | PARP10 3012/4885PARP2 4692/4885PARP4 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.